We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

By LabMedica International staff writers
Posted on 18 Feb 2026

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access to scalable, high-quality, cost-efficient solutions across select markets outside the U. More...

S.

The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of over 70 assays on these new partner platforms.

These additions are planned to increase QuidelOrtho's ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger, high-throughput environments that require scalable capacity and broad test menus. The commercial focus will be on Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and the Asia-Pacific regions. This strategic expansion is planned to support QuidelOrtho's ability to address menu gaps, increase competitiveness in international tenders, and deliver more complete immunoassay solutions to laboratories seeking broader menus and flexible system options.

"Through our collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long-term innovation strategy in core growth markets,” said Bryan Hanson, Senior Vice President of Global Clinical Laboratory and Transfusion Medicine at QuidelOrtho. “This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions."

"This strategic partnership with QuidelOrtho marks an important milestone in Lifotronic Technology's global expansion strategy,” added Liu Xiancheng, Chairman of Lifotronic Technology. “Going forward, we will work closely with QuidelOrtho, continuing to leverage our in-house R&D strengths to deliver high-value diagnostic solutions that meet real clinical needs for customers worldwide."

Related Links:
QuidelOrtho
Lifotronic Technology


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AI blood-based cell-free DNA analyses detect early liver fibrosis and other diseases (Photo courtesy of Shutterstock)

AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals

Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.